Professor Tom Foltynie is Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London. He is responsible for Movement disorder patients, particularly Parkinson’s disease (PD) patients undergoing advanced treatments such as Deep Brain Stimulation (DBS), Apomorphine and Duodopa. He  is chief investigator for a series of trials of Exenatide- a potential neurorestorative treatment for PD, as well as the lead clinician at UCL for trials of alpha synuclein vaccination for PD and Oxford Biomedica/ Axovant’s gene therapy product for PD, and the Transeuro PD cell transplantation programme.

Professor Foltynie has published clinical trials of DBS as a treatment for the cognitive problems associated with advanced PD/DLB, as well as successful results of a trial of Deep Brain Stimulation for the treatment of patients with severe Tourette syndrome.  He is interested in the mechanisms of action of DBS as elucidated using functional MRI, and developing ways of providing therapeutic DBS with better benefit to side effect ratios.